About Careers Internship MedBlog Contact us

New Experimental Anti-viral Drug Offers Promise in Fight Against Measles

by Sheela Philomena on April 17, 2014 at 8:53 AM
Font : A-A+

 New Experimental Anti-viral Drug Offers Promise in Fight Against Measles

A novel experimental anti-viral drug when taken orally could help contribute to measles eradication, show clinical trial results.

The drug, so far tested on animals, has been effective on a virus closely related to the one that causes measles, having reduced virus levels and prevented death.


Despite major progress to contain the highly-contagious disease worldwide, measles has caused around 150,000 deaths annually since 2007, according to the study, which appeared in the journal Science Translational Medicine.

A European resurgence of the measles-causing morbillivirus, previously considered contained on that continent, is due in large part to insufficient vaccination rates, mostly because parents opt out of vaccinating their children.

Researchers tested the drug, ERDRP-0519, on the canine distemper virus, which is deadly in ferrets.

Treatment with the new antivirus, which blocks replication of the pathogen, allowed the animals to survive infection, remain disease-free and develop a robust immunity against the virus.

- Not a vaccine alternative -

"The emergence of strong antiviral immunity in treated animals is particularly encouraging, since it suggests that the drug may not only save an infected individual from disease but contribute to closing measles immunity gaps in a population," said Richard Plemper of the Institute for Biomedical Sciences at Georgia State University.

The new antivirus was developed by the facility, along with the Emory Institute for Drug Development and the Paul-Ehrlich-Institute in Germany.

The treatment, which "can be produced cost-effectively, stockpiled and administered by mouth, could boost eradication efforts by rapidly suppressing the spread of the virus during local outbreaks," a statement by Georgia State University said.

The drug should be effective in treating friends, family and others who may have come in contact with a measles-infected person but are not yet demonstrating symptoms, Plemper said.

But the treatment is not meant to be the primary means for fighting measles, Plemper said.

"We really want to emphasize and make very clear that this drug was not developed as a possible alternative to vaccination," he said.

Plemper added that a 90 percent vaccination rate was needed for a population to prevent transmission of the disease.

In Europe, however, the vaccination rate varies between 60 and 90 percent depending on the country. In the United States, the rate exceeds 90 percent.

The researches noted that the virus could develop resistance to the antiviral drug. But the study also showed that the resistant viruses were usually less virulent and their transmission was impaired compared with non-resistant strains.

Scientists will next test the drug on monkeys before doing clinical trials on humans in the next few years, Plemper added.

One in three unvaccinated people who contract the measles develop pneumonia or inflammation of the brain, the researchers said.

Source: AFP


Recommended Readings

Latest Clinical Trials News

How Targeted Therapy Achieves Responses Across Multiple Cancer Types?
Erdafitinib is the first approved FGFR-targeted treatment for advanced urothelial cancer, reveal scientists.
Parkinson's Disease Drug Ropinirole Slows Progression of ALS
Amyotrophic lateral sclerosis patients' motor neurons responded robustly to Parkinson's drug ropinirole.
 Nanorobots: A Revolutionary Tool in Targeting Fungal Infections
A new way to quickly eliminate fungal infections in the mouth has been developed by researchers at Penn Dental and Penn Engineering, using magnetically guided nanorobots.
 Gene Therapy Using Adeno Virus Reverses Age-Related Hearing Loss
Researchers tested the effectiveness of virus-mediated gene therapy for genetic hearing loss in an aged mouse model with genetic changes related to deafness.
Stickers Promise a Painless Mode of Measles Vaccine Delivery
The outcomes of the first clinical trial demonstrate the safety and efficacy of the measles-rubella (MR) vaccination to adults and infants as young as 9 months.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

New Experimental Anti-viral Drug Offers Promise in Fight Against Measles Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests